Literature DB >> 21683269

Comparative activities of daptomycin and several agents against staphylococcal blood isolates. Glycopeptide tolerance.

Juan J Picazo1, Carmen Betriu, Iciar Rodríguez-Avial, Esther Culebras, Fátima López-Fabal, María Gómez.   

Abstract

The activity of daptomycin was evaluated against 702 staphylococcal blood isolates (316 methicillin-susceptible Staphylococcus aureus, 187 methicillin-resistant S. aureus [MRSA], and 199 coagulase-negative staphylococci [CoNS]) collected in 41 Spanish hospitals. Glycopeptide tolerance and the incidence of heterogeneous glycopeptide-intermediate (hGISA) isolates were also examined. Vancomycin MICs determined by the Etest were compared with those obtained by the reference broth microdilution method. Daptomycin exhibited good activity, and only 2 isolates were nonsusceptible to this antibiotic. Resistance to linezolid was observed in 2 MRSA isolates and in 16 CoNS. The cfr gene was detected in 7 of these 18 isolates. Vancomycin and teicoplanin tolerance was 9.6% and 21.9%, respectively, in MRSA isolates. We detected the hGISA phenotype in 5.8% of MRSA isolates. Vancomycin MICs by the Etest were slightly higher than those obtained by broth microdilution. Daptomycin retained activity against isolates that were not susceptible to linezolid, teicoplanin, or quinupristin-dalfopristin.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21683269     DOI: 10.1016/j.diagmicrobio.2011.02.009

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  4 in total

1.  Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries.

Authors:  A Canut; A Isla; C Betriu; A R Gascón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-28       Impact factor: 3.267

2.  Epidemiology and prognosis of coagulase-negative staphylococcal endocarditis: impact of vancomycin minimum inhibitory concentration.

Authors:  Cristina García de la Mària; Carlos Cervera; Juan M Pericàs; Ximena Castañeda; Yolanda Armero; Dolors Soy; Manel Almela; Salvador Ninot; Carlos Falces; Carlos A Mestres; Jose M Gatell; Asuncion Moreno; Francesc Marco; José M Miró
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

Review 3.  The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis.

Authors:  Aref Shariati; Masoud Dadashi; Zahra Chegini; Alex van Belkum; Mehdi Mirzaii; Seyed Sajjad Khoramrooz; Davood Darban-Sarokhalil
Journal:  Antimicrob Resist Infect Control       Date:  2020-04-22       Impact factor: 4.887

4.  Brazilian experience in EU-CORE: daptomycin registry and treatment of serious Gram-positive infections.

Authors:  Artur Timerman; Carlos Brites; Eliana Bicudo; Renato S Grinbaum; Rubens Costa Filho; Claudia D M Carrilho; Andre Bichels; Tânia Barreto
Journal:  Braz J Infect Dis       Date:  2013-07-31       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.